Fundraising FoxNuvOx Therapeutics
Tucson, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into NuvOx Therapeutics
141 people in our graph share verified history with the NuvOx Therapeutics team — schools, employers, funds. One of them is your warm intro.
Elizabeth Cho-Fertikhunlockedknows Rong Wang · together at NuvOx Therapeutics (overlapped)
knows the team · via Microvascular Therapeutics
knows the team · via Microbion Corporation
×6knows the team · via The University of Arizona Health Network
×3knows the team · via Ventana Medical Systems
NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.
Founders & leadership
NuvOx Therapeutics was founded in 2022 by Evan Unger.
EU
Evan UngerCo-Founder and Executive ChairmanEvan Unger is a board-certified radiologist and Professor Emeritus of Medical Imaging at the University of Arizona with expertise in minimally invasive imaging techniques and contrast media research. He holds over 120 US patents and previously founded a company acquired by DuPont; he currently serves as Executive Officer and Director of NuvOx Therapeutics.
RW
Rong WangPresident and CEORong Wang has held executive positions across Fortune 500 companies and investor-backed firms, with experience in strategy execution and stakeholder management across multiple organizations.
JJ
Jennifer JohnsonChief Operating OfficerJennifer Johnson holds a Ph.D. in Pharmaceutics and Drug Design from the University of Arizona and brings over 20 years of experience in pharmaceutical research, regulatory affairs, and quality systems, including submissions to the FDA and international regulators. She has led R&D and regulatory teams and holds multiple patents in formulation design and drug delivery.
Board
MJ
Marvin J. SlepianBoard director
RC
Richard CarmonaBoard director
JT
Jonathan T. SchillingBoard director
JS
Jon SaxeBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 2 rounds · 2023–2024
▶$235KraisedNov 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$235KraisedNov 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marvin J. SlepianDirector
- Richard CarmonaDirector
- Jonathan T. SchillingDirector
- Jon SaxeDirector
- Rong WangExecutive Officer
- Evan UngerExecutive Officer, Director
- Jennifer JohnsonExecutive Officer
- Offering amount
- $7M
- Amount sold
- $235K
- Minimum investment
- $35K
- Sales commissions
- $405.9K
- Placement agents
- Donald Capital, LLC
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$1.1MraisedFeb 2023 · 2 investors · Other Health CareRule 506(b)
▶$1.1MraisedFeb 2023 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jon SaxeDirector
- Marvin SlepianDirector
- Richard CarmonaDirector
- Rong WangExecutive Officer
- Evan C UngerExecutive Officer, Director
- Jonathan SchillingDirector
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Renovo Rx8 shared keywordsRenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
Medscape7 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Nuvalent7 shared keywordsNuvalent is a biopharmaceutical company that uses chemistry and structure-based drug discovery to design small-molecule kinase inhibitors as precisely targeted cancer therapies. Its clinical-stage programs address ROS1-, ALK-, and HER2-altered non-small cell lung cancer and other solid tumors.
Companies competing with NuvOx Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does NuvOx Therapeutics do?
- NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.
- Who founded NuvOx Therapeutics?
- NuvOx Therapeutics was founded by Evan Unger in 2022.
- Who are NuvOx Therapeutics's investors?
- NuvOx Therapeutics's investors include Pasadena Angels.
- How much funding has NuvOx Therapeutics raised?
- NuvOx Therapeutics has disclosed $1.3M raised across 2 rounds.
- Where is NuvOx Therapeutics headquartered?
- NuvOx Therapeutics is headquartered in Tucson, US.